Fossil Group, Myriad Genetics Among The Earnings Reports To Keep An Eye On Tuesday
Fossil Group Inc (NASDAQ: FOSL), Cree, Inc. (NASDAQ: CREE), Symantec Corporation (NASDAQ: SYMC) and Myriad Genetics, Inc. (NASDAQ: MYGN) are scheduled to announce their quarterly financial results on Tuesday evening, after the market closes. So, let’s take a look at what the Street, the crowd and management are expecting for the calls.
Although Fossil’s management guided earnings in the $1.18 per share - $1.29 per share range, and revenues of $804.77 million to $820.25 million, substantially up year-over-year, the market is expecting something quite different.
For the second quarter of the year, the Street is modeling consensus earnings of $0.84 per share on revenue of $751.57 million, while the crowd is projecting earnings of $0.92 per share on revenue of $762.02 million (Estimize).
These figures imply a decline of at least 6 percent from the earnings of $0.98 per share (on revenue of $774 million) reported in the second quarter of 2014 and almost flat earnings when compared to last quarter’s $0.91 per share – on sales of $725 million.
However, it should be noted in the chart above that Fossil has a history of surpassing both estimates and guidance.
Similar is the case for Cree. Management has guided earnings of $0.26 per share on revenue of $430 million, down from EPS of $0.42 on sales of $436.3 million reported a year ago, but up from last quarter’s EPS of $0.22 and revenue of $409.52 million.
Nonetheless, the crowd seems more bearish and anticipates earnings of $0.00 per share on revenue of $387.08 million.
The most pessimistic is the Street, which expects a consensus net loss of ($0.08) per share and revenue of $384.9 million.
Symantec & Myriad Genetics
A year ago, Symantec reported first quarter (fiscal 2015) earnings of $0.45 per share on revenue of $1.735 billion. For the current quarter (Q1 fiscal 2016), management, the Street and the crowd are expecting earnings of $0.43 per share on revenue in the range of $1.52 billion to $1.525 billion.
Finally, there’s Myriad Genetics, which is also expected to post a small year-over-year decline in earnings, from $0.48 per share reported a year ago to $0.41 per share this quarter.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.